You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2024

Investigational Drug Information for Sutezolid


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Sutezolid?

Sutezolid is an investigational drug.

There have been 6 clinical trials for Sutezolid. The most recent clinical trial was a Phase 1 trial, which was initiated on January 1st 2023.

The most common disease conditions in clinical trials are Tuberculosis, Tuberculosis, Pulmonary, and [disabled in preview]. The leading clinical trial sponsors are Global Alliance for TB Drug Development, University of California, San Francisco, and Michael Hoelscher.

There are twenty-one US patents protecting this investigational drug and two hundred and eighty-five international patents.

Recent Clinical Trials for Sutezolid
TitleSponsorPhase
Trial of Novel Regimens for the Treatment of Pulmonary TuberculosisTB AlliancePhase 2
Trial of Novel Regimens for the Treatment of Pulmonary TuberculosisNational Institute of Allergy and Infectious Diseases (NIAID)Phase 2
Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary TuberculosisGlobal Alliance for TB Drug DevelopmentPhase 2

See all Sutezolid clinical trials

Clinical Trial Summary for Sutezolid

Top disease conditions for Sutezolid
Top clinical trial sponsors for Sutezolid

See all Sutezolid clinical trials

US Patents for Sutezolid

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sutezolid ⤷  Sign Up Anti-CS1 antibodies and antibody drug conjugates AbbVie Biotherapeutics Inc. (Redwood City, CA) ⤷  Sign Up
Sutezolid ⤷  Sign Up Compounds, compositions and methods Denali Therapeutics Inc. (South San Francisco, CA) ⤷  Sign Up
Sutezolid ⤷  Sign Up Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign Up
Sutezolid ⤷  Sign Up Anti-huLRRC15 antibody drug conjugates and methods for their use AbbVie Inc. (North Chicago, IL) AbbVie Biotherapeutics Inc. (Redwood City, CA) ⤷  Sign Up
Sutezolid ⤷  Sign Up Anti-huLRRC15 antibody drug conjugates and methods for their use AbbVie Inc. (North Chicago, IL) AbbVie Biotherapeutics Inc. (Redwood City, CA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sutezolid

Drugname Country Document Number Estimated Expiration Related US Patent
Sutezolid Australia AU2015339012 2034-10-31 ⤷  Sign Up
Sutezolid Brazil BR112017008945 2034-10-31 ⤷  Sign Up
Sutezolid Canada CA2966005 2034-10-31 ⤷  Sign Up
Sutezolid European Patent Office EP3212668 2034-10-31 ⤷  Sign Up
Sutezolid Spain ES2832711 2034-10-31 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.